Alkem Laboratories has, pursuant to a shareholders’ agreement dated August 12, 2025, has planned to incorporate a subsidiary company (Subsidiary) in the Kingdom of Saudi Arabia. Pursuant to incorporation of such subsidiary, the company will hold 51% of the total share capital. The balance stake of 49% will be held by Abdulaziz Alsheikh (Saudi Partner).
The proposed investment in the Subsidiary is a strategic investment undertaken by the company with the objective of expanding the company’s business and market reach to the Kingdom of Saudi Arabia. The Subsidiary is proposed to be incorporated as a limited liability company and will be involved in the manufacture, import, marketing and distribution of pharmaceutical and/or nutraceutical products within the Kingdom of Saudi Arabia.
Alkem Laboratories is among India’s leading global pharmaceutical companies. The company develops, manufactures and markets high-quality pharmaceutical products across all major therapeutic segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1837.15 |
| Dr. Reddys Lab | 1271.55 |
| Cipla | 1353.85 |
| Zydus Lifesciences | 1070.90 |
| Lupin | 2351.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: